Abstract Details

Title Trends In Outpatient And Hospitalization Charges Relevant To the Management of Chronic Inflammatory Demyelinating Polyneuropathy: A Statewide Planning and Research Cooperative System (SPARCS) Study 2002-2014

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P2 - Poster Session 2 (5:30 PM-6:30 PM)

Poster/Presentation
Number 12-004

Objective To investigate trends in inpatient and outpatient charges relevant to IVIG, plasmapheresis, and steroid administration from 2002-2014 for the management of CIDP.

Background There are several options for CIDP management.

Design/Methods Patients from 2002-2014 were retrieved from the Statewide Planning and Research Cooperative System (SPARCS) database using the ICD 9 code for CIDP. Charges on outpatient and inpatient services per patient as well as the average inpatient admission times were compared on a year-by-year basis to determine the overall trend from 2002-2014.

Results

We identified 2850 CIDP patients. The overall charges in outpatient services demonstrated an increasing trend between 2002-2014. For outpatient charges between 2002 and 2014, IVIG represented an average charge of 56% ± 13%, plasmapheresis represented 39% ± 17%, and corticosteroids represented 5% ± 7.8%. The outpatient charges per patient has increased from 2002 ($7,595) to 2014 ($132,696).

The overall trend from 2005-2014 for outpatients who required inpatient services was decreasing (y=-0.0257x+0.9417). Between 2005 and 2010, the frequency in which outpatients were admitted as inpatients ranged from 0.75 to 1.05 times per year. Between 2011 and 2014, the frequency in which patients were admitted as inpatients ranged from to 0.56 to 0.74 times per year.

Conclusions Our data demonstrated an increased average charge of CIDP management between 2002-2014 as an outpatient that was paralleled by a reduction in the frequency of inpatient admissions. Work in progress to determine trends in charges relevant to inpatient setting as well as to specific CIDP treatments.

Authors/Disclosures
Anil Thatikonda PRESENTER	No disclosure on file
Kevin Nolasco	Kevin Nolasco has nothing to disclose.
Sanjila Islam, MD (Rutgers New Jersey Medical School)	Dr. Islam has nothing to disclose.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��